XML 28 R2.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 28, 2024

Dec. 30, 2023

Dec. 31, 2022

Dec. 25, 2021

Dec. 26, 2020

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table

Pay Versus Performance

As a result of the rules adopted by the SEC under the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation

S-K

(“PvP Rules”), we are providing the following information about the relationship between “compensation actually paid” to our CEO (referred to below as our Principal Executive Officer or PEO) and average “compensation actually paid” to our other NEOs and certain metrics of our financial performance for the last three years, in each case, calculated in accordance with the PvP Rules.

For purposes of this disclosure, “compensation actually paid” or “CAP” to our PEO and other NEOs represents an amount calculated based on the SEC’s prescribed formula. CAP is not compensation actually earned by or paid to our named executive officers in each respective year. Neither the Compensation Committee nor the executives of our Company directly used the information in this table or the related disclosures when making compensation decisions for 2024. For details about the Company’s

pay-for-performance

philosophy and how the Compensation Committee makes its decisions about executive pay, see the Compensation Discussion and Analysis beginning on page 34 of this proxy statement.

Pay Versus Performance Table


										Value of initial fixed $100 investment based on
Year		Summary Compensation Table Total for PEO		Compensation Actually Paid to PEO 1		Average Summary Compensation Table Total for non-PEO NEOs		Average Compensation Actually Paid to Non-PEO NEOs 2		Total Shareholder Return 3		Peer Total Shareholder Return 3		Net Income/ (Loss) (in millions)		Company-Selected Measure: Non-GAAP EPS 4
	2024		$11,640,272		$7,852,214		$3,193,394		$2,322,504		$106		$144		$398		$4.74
	2023		$10,005,729		$4,941,292		$2,807,442		$1,705,337		$114		$139		$436		$4.50
	2022		$8,255,135		$9,962,917		$2,945,446		$3,402,202		$120		$136		$566		$5.38
	2021		$10,786,180		$28,293,056		$3,854,485		$7,569,084		$113		$142		$660		$5.05
	2020		$6,239,637		($8,384,241)		$2,649,163		($811,730)		$99		$114		$419		$3.53

The dollar amounts reported in this column represent the CAP to our PEO, Mr. Bergman, as computed in accordance with PvP Rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Mr. Bergman during the applicable year.

The dollar amounts reported in this column represent the CAP to our

Non-PEO

NEOs as a group, as computed in accordance with PvP Rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to the

Non-PEO

NEOs as a group during the applicable year.

Cumulative shareholder returns reflect $100 invested as of market close on December 27, 2019, the final trading day of the Company’s fiscal year ended December 28, 2019 (“fiscal 2019”); Peer Total Shareholder Return based on Dow Jones U.S. Health Care Index; see Stock Performance Graph included in Part II, Item 5 of our Annual Report on Form

10-K

for the year ended December 28, 2024, as filed with the SEC on February 25, 2025.

Reflects the Company’s selected measure of

Non-GAAP

EPS which is consistently calculated for each year reflected in the table (see chart below). The adjusted EPS used in the incentive plans (HSIP and PSUs) may reflect other adjustments which are generally described in the Compensation Discussion and Analysis.


	2020		2021		2022		2023		2024
GAAP diluted EPS from continuing operations attributable to Henry Schein, Inc.		$2.81		$4.45		$3.91		$3.16		$3.05

Non-GAAP Adjustments, net of tax and attribution to noncontrolling interests:
Restructuring and integration costs		$0.17		$0.03		$0.74		$0.40		$0.62
Acquisition intangible amortization		Excluded		Excluded		Excluded		$0.70		$0.88
Litigation settlements		-		$0.08		-		-		$0.03
Cybersecurity Incident- insurance proceeds, net of third-party advisory expenses		-		-		-		$0.06		$(0.18)
Impairment of intangible assets		Excluded		-		$0.16		$0.04		-
Impairment of capitalized assets		-		-		-		$0.14		$0.05
Change in contingent consideration		-		-		-		-		$0.28
Costs associated with shareholder advisory matters		-		-		-		-		$0.01
Gain on sale of equity investments		$(0.01)		$(0.05)		-		-		-

Non-GAAP diluted EPS attributable to Henry Schein, Inc., as presented		$2.97		$4.51		$4.81		$4.50		$4.74
Reconciling items to present non-GAAP diluted EPS attributable to Henry Schein, Inc. on a consistent basis:
Acquisition intangible amortization		$0.48		$0.54		$0.57		-		-
Impairment of intangible assets		$0.08		-		-		-		-
Non-GAAP diluted EPS attributable to Henry Schein, Inc., on a consistent basis 1		$3.53		$5.05		$5.38		$4.50		$4.74

The Company revised its calculation of

non-GAAP

diluted EPS in fiscal 2023. As such, the Company adjusted the calculation of

non-GAAP

diluted EPS for fiscal 2020, fiscal 2021 and fiscal 2022 to be consistent with the calculation of

non-GAAP

diluted EPS used in fiscal 2023 and fiscal 2024.

Reconciliation Tables

The following table sets forth a reconciliation from the Summary Compensation Table (“SCT”) to CAP to our PEO. Mr. Bergman served as our only PEO for each year.


Year	SCT Total (a)	Less Equity Deduction from SCT Total 1 (b)	Value of Current Year Equity Awards at Year-end 2 (c)	Change in Value of Unvested Prior Year Awards During Year 3 (d)	Change in Value of Prior Year Awards That Vested During Year 4 (e)	Total Compensation Actually Paid 5 (a + b + c + d + e)
2024	$11,640,272	($7,764,800)	$5,395,792	($1,428,384)	$9,334	$7,852,214
2023	$10,005,729	($7,395,000)	$4,370,663	($1,726,122)	($313,978)	$4,941,292
2022	$8,255,135	($3,971,000)	$2,850,094	$1,434,350	$1,394,338	$9,962,917
2021	$10,786,180	($5,770,209)	$7,378,604	$15,932,034	($33,552)	$28,293,056
2020	$6,239,637	($3,438,000)	$0	($10,977,620)	($208,258)	($8,384,241)

Represents the grant date fair value of equity-based awards made during the fiscal year based on the amounts reported in the “Stock Awards” and “Option Awards” columns in the SCT for the applicable year.

Represents the

year-end

fair value of equity awards that were made during the fiscal year (no grants made during a fiscal year vested during the same fiscal year).

Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of

year-end.

Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year.

SCT total, less SCT equity grant date fair value, plus

year-end

fair value of equity awards made during the year, plus the change in fair value during the year of equity awards that remained unvested as of

year-end,

plus the change in fair value of equity awards that vested during the year.

The following table sets forth a reconciliation from the SCT to CAP to our average

Non-PEO

NEO. Our

non-PEO

NEOs by year are as follows: 2024 and 2023 – Messrs. South, Mlotek, Ettinger and Breslawski; 2022 – Messrs. South, Paladino, Connett, Mlotek and Breslawski; 2021 and 2020 – Messrs. Paladino, Benjamin, Mlotek and Breslawski.


Year	SCT Total (a)	Less Equity Deduction from SCT Total 1 (b)	Value of Current Year Equity Awards at Year-end 2 (c)	Change in Value of Unvested Prior Year Awards During Year 3 (d)	Change in Value of Prior Year Awards That Vested During Year 4 (e)	Total Compensation Actually Paid 5 (a –b + c + d + e)
2024	$3,193,394	($1,703,125)	$1,187,862	($364,536)	$8,909	$2,322,504
2023	$2,807,442	($1,565,500)	$1,063,479	($555,301)	($44,784)	$1,705,337
2022	$2,945,446	($1,441,433)	$1,179,477	$353,110	$365,601	$3,402,202
2021	$3,854,485	($2,174,430)	$2,805,529	$3,118,145	($34,646)	$7,569,084
2020	$2,649,163	($1,473,250)	$560,510	($2,401,561)	($146,591)	($811,730)

Represents the

year-end

fair value of equity awards that were made during the fiscal year (no grants made during a fiscal year vested during the same fiscal year).

Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of

year-end.

Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year.

SCT total, less SCT equity grant date fair value, plus

year-end

fair value of equity awards made during the year, plus the change in fair value during the year of equity awards that remained unvested as of

year-end,

plus the change in fair value of equity awards that vested during the year.

The Company grants PSUs to executive officers annually, although no such grant was made during 2021. The Company grants RSUs to executive officers annually. Such grants cliff-vest on the fourth anniversary of the grant. During 2021, certain equity awards were granted as RSUs that vested 50% on the first anniversary of the grant in 2022 and 50% on the second anniversary of the grant in 2023.

The Company granted stock options to executive officers in 2021 and 2022 as part of the annual equity grant. Grants vest and become exercisable in

one-third

increments on the first three anniversaries of the grant and expire on the 10

anniversary of the grant (subject to earlier expiration based on certain employment terminations). Fair values at time of the grant, at

year-end

2023 and 2024, and on vesting dates for awards that vested during 2024 were all determined using the Black-Scholes model. The table below summarizes the option fair values and related assumptions used to calculate CAP for fiscal years 2023 and 2024. None of the options granted to NEOs have been exercised as of

year-end

2024.


Valuation Purpose for PVP	HSIC Stock Price	HSIC Option Exercise Price	Expected Term (years)	Stock Price Volatility	Risk-free Interest Rate	Dividend Yield	Option Fair Value
Year-end 2023	$75.71	$62.71-$86.27	3.2 – 4.2	28.5%	3.86%	0%	$18.35-$25.58
2024 Vesting	$74.58-$76.88	$62.71-$86.27	3.0 – 4.0	28.2%	4.17%-4.33%	0%	$17.36-$26.22
Year-end 2024	$70.42	$86.27	3.2	28.1%	4.50%	0%	$12.39

Company Selected Measure Name

Non-GAAP EPS

Named Executive Officers, Footnote

Our

non-PEO

Peer Group Issuers, Footnote

10-K

for the year ended December 28, 2024, as filed with the SEC on February 25, 2025.

PEO Total Compensation Amount

$ 11,640,272

$ 10,005,729

$ 8,255,135

$ 10,786,180

$ 6,239,637

PEO Actually Paid Compensation Amount

$ 7,852,214

4,941,292

9,962,917

28,293,056

(8,384,241)

Adjustment To PEO Compensation, Footnote

Reconciliation Tables

The following table sets forth a reconciliation from the Summary Compensation Table (“SCT”) to CAP to our PEO. Mr. Bergman served as our only PEO for each year.


Year	SCT Total (a)	Less Equity Deduction from SCT Total 1 (b)	Value of Current Year Equity Awards at Year-end 2 (c)	Change in Value of Unvested Prior Year Awards During Year 3 (d)	Change in Value of Prior Year Awards That Vested During Year 4 (e)	Total Compensation Actually Paid 5 (a + b + c + d + e)
2024	$11,640,272	($7,764,800)	$5,395,792	($1,428,384)	$9,334	$7,852,214
2023	$10,005,729	($7,395,000)	$4,370,663	($1,726,122)	($313,978)	$4,941,292
2022	$8,255,135	($3,971,000)	$2,850,094	$1,434,350	$1,394,338	$9,962,917
2021	$10,786,180	($5,770,209)	$7,378,604	$15,932,034	($33,552)	$28,293,056
2020	$6,239,637	($3,438,000)	$0	($10,977,620)	($208,258)	($8,384,241)

Represents the

year-end

fair value of equity awards that were made during the fiscal year (no grants made during a fiscal year vested during the same fiscal year).

Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of

year-end.

Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year.

SCT total, less SCT equity grant date fair value, plus

year-end

fair value of equity awards made during the year, plus the change in fair value during the year of equity awards that remained unvested as of

year-end,

plus the change in fair value of equity awards that vested during the year.

The Company granted stock options to executive officers in 2021 and 2022 as part of the annual equity grant. Grants vest and become exercisable in

one-third

increments on the first three anniversaries of the grant and expire on the 10

anniversary of the grant (subject to earlier expiration based on certain employment terminations). Fair values at time of the grant, at

year-end

2024.


Valuation Purpose for PVP	HSIC Stock Price	HSIC Option Exercise Price	Expected Term (years)	Stock Price Volatility	Risk-free Interest Rate	Dividend Yield	Option Fair Value
Year-end 2023	$75.71	$62.71-$86.27	3.2 – 4.2	28.5%	3.86%	0%	$18.35-$25.58
2024 Vesting	$74.58-$76.88	$62.71-$86.27	3.0 – 4.0	28.2%	4.17%-4.33%	0%	$17.36-$26.22
Year-end 2024	$70.42	$86.27	3.2	28.1%	4.50%	0%	$12.39

Non-PEO NEO Average Total Compensation Amount

$ 3,193,394

2,807,442

2,945,446

3,854,485

2,649,163

Non-PEO NEO Average Compensation Actually Paid Amount

$ 2,322,504

1,705,337

3,402,202

7,569,084

(811,730)

Adjustment to Non-PEO NEO Compensation Footnote

The following table sets forth a reconciliation from the SCT to CAP to our average

Non-PEO

NEO. Our

non-PEO


Year	SCT Total (a)	Less Equity Deduction from SCT Total 1 (b)	Value of Current Year Equity Awards at Year-end 2 (c)	Change in Value of Unvested Prior Year Awards During Year 3 (d)	Change in Value of Prior Year Awards That Vested During Year 4 (e)	Total Compensation Actually Paid 5 (a –b + c + d + e)
2024	$3,193,394	($1,703,125)	$1,187,862	($364,536)	$8,909	$2,322,504
2023	$2,807,442	($1,565,500)	$1,063,479	($555,301)	($44,784)	$1,705,337
2022	$2,945,446	($1,441,433)	$1,179,477	$353,110	$365,601	$3,402,202
2021	$3,854,485	($2,174,430)	$2,805,529	$3,118,145	($34,646)	$7,569,084
2020	$2,649,163	($1,473,250)	$560,510	($2,401,561)	($146,591)	($811,730)

Represents the

year-end

fair value of equity awards that were made during the fiscal year (no grants made during a fiscal year vested during the same fiscal year).

Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of

year-end.

Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that vested during the current fiscal year.

SCT total, less SCT equity grant date fair value, plus

year-end

fair value of equity awards made during the year, plus the change in fair value during the year of equity awards that remained unvested as of

year-end,

plus the change in fair value of equity awards that vested during the year.

The Company granted stock options to executive officers in 2021 and 2022 as part of the annual equity grant. Grants vest and become exercisable in

one-third

increments on the first three anniversaries of the grant and expire on the 10

anniversary of the grant (subject to earlier expiration based on certain employment terminations). Fair values at time of the grant, at

year-end

2024.


Valuation Purpose for PVP	HSIC Stock Price	HSIC Option Exercise Price	Expected Term (years)	Stock Price Volatility	Risk-free Interest Rate	Dividend Yield	Option Fair Value
Year-end 2023	$75.71	$62.71-$86.27	3.2 – 4.2	28.5%	3.86%	0%	$18.35-$25.58
2024 Vesting	$74.58-$76.88	$62.71-$86.27	3.0 – 4.0	28.2%	4.17%-4.33%	0%	$17.36-$26.22
Year-end 2024	$70.42	$86.27	3.2	28.1%	4.50%	0%	$12.39

Compensation Actually Paid vs. Total Shareholder Return

The following chart sets forth the relationship between PEO CAP, the average of other NEOs CAP and our TSR during fiscal years 2020 through 2024 versus the Dow Jones U.S. Health Care Index.

Compensation Actually Paid vs. Net Income

The following chart sets forth the relationship between PEO CAP, the average of other NEOs CAP and our net income during fiscal years 2020 through 2024.

Compensation Actually Paid vs. Company Selected Measure

The following chart sets forth the relationship between PEO CAP, the average of other NEOs CAP and our

non-GAAP

EPS during fiscal years 2020 through 2024.

Total Shareholder Return Vs Peer Group

The following chart sets forth the relationship between PEO CAP, the average of other NEOs CAP and our TSR during fiscal years 2020 through 2024 versus the Dow Jones U.S. Health Care Index.

Tabular List, Table

Most Important Financial Measures

The following table sets forth financial performance measures that we considered to be the most important in how CAP was linked to Company performance during 2024. As discussed in the Compensation Discussion and Analysis beginning on page 34 of this proxy statement, the annual HSIP uses adjusted EPS as a financial metric for all NEOs and cumulative EPS is a financial metric used for PSU grants for the 2020-2022, 2022-2024, 2023-2025 and 2024-2026 cycles (no PSU grants were made for 2021-2023). The annual HSIP also uses revenue and operating income as a financial metric for our NEOs. The PSU grants for the 2023-2025 and 2024-2026 cycle also include Return on Invested Capital as a financial metric.